Posted by Michael Wonder on 22 May 2026
The EMA accepts Teva’s marketing authorisation application for olanzapine long-acting injectable for the treatment of schizophrenia in adults
21 May 2026 - Teva Pharmaceuticals and Medincell today announced that the EMA has accepted the marketing authorisation application for olanzapine long-acting injectable (TEV-‘749) for the treatment of schizophrenia in adults.
TEV-‘749 aims to address treatment adherence in real world settings and contribute to long-term disease management in people living with schizophrenia.
